Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Net Cash Flow (2022 - 2025)

Historic Net Cash Flow for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $1.5 million.

  • Zentalis Pharmaceuticals' Net Cash Flow fell 6566.43% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.2 million, marking a year-over-year increase of 9676.23%. This contributed to the annual value of $5.8 million for FY2024, which is 13878.61% up from last year.
  • According to the latest figures from Q3 2025, Zentalis Pharmaceuticals' Net Cash Flow is $1.5 million, which was down 6566.43% from -$4.3 million recorded in Q2 2025.
  • Zentalis Pharmaceuticals' Net Cash Flow's 5-year high stood at $230.3 million during Q2 2023, with a 5-year trough of -$155.8 million in Q3 2023.
  • Over the past 4 years, Zentalis Pharmaceuticals' median Net Cash Flow value was -$640000.0 (recorded in 2024), while the average stood at -$1.4 million.
  • Data for Zentalis Pharmaceuticals' Net Cash Flow shows a peak YoY increase of 84655.54% (in 2023) and a maximum YoY decrease of 1605733.59% (in 2023) over the last 5 years.
  • Zentalis Pharmaceuticals' Net Cash Flow (Quarter) stood at $518000.0 in 2022, then crashed by 16057.34% to -$82.7 million in 2023, then soared by 91.02% to -$7.4 million in 2024, then skyrocketed by 119.85% to $1.5 million in 2025.
  • Its Net Cash Flow was $1.5 million in Q3 2025, compared to -$4.3 million in Q2 2025 and $8.0 million in Q1 2025.